Enlivex Therapeutics Ltd. - ENLV Accounting Value per Share
Enlivex Therapeutics (ENLV) is implementing advanced methods to combat cytokine storms by reprogramming immune cells. Production facilities and laboratories are operating stably, scaling the output of drugs. However, geopolitical instability in Israel creates risks for clinical processes. The adjusted book value of the share presented in GURU.Markets demonstrates a financial base where the 230.82 metric determines this level of company stability.
%20Net%20Assets%20per%20Single%20Share&width=1200&height=400&colorIndex=0&v=mvt4kixj.9g-7avve2o&start=20220704&end=20261029&filename=GURU_Markets_-_ENLV_-_Enlivex-Therapeutics_-_Net-Assets-per-Single-Share "ENLV (Enlivex Therapeutics Ltd) Net Assets per Single Share history from 07/04/2022 to 10/29/2026 | 👁️GURU.Markets👁️")
Summary analytical data breakdowns for Enlivex Therapeutics Ltd (ENLV)
- current quotes and average value forecast:
- issuer market value details:
- balance sheet net asset value indicators:
- company total debt and liquidity indicators:
Total Debt to Capital Enlivex Therapeutics|ENLV - Long-Term Debt to Capital|Short-Term Debt to Equity Enlivex Therapeutics, Ltd.|ENLV - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Enlivex Therapeutics Ltd.|ENLV - Company Long-Term Liabilities|Company Short-Term Debts Enlivex Therapeutics
General company analysis:ENLV - enlivex.com
The complexity of industrial biomanufacturing and stringent regulatory oversight of cell therapy at Enlivex Therapeutics (ENLV) directly impact its capital expenditure structure. The BVPS trend reflects the value of net assets per share, where an upward trend confirms capital accumulation and a decline indicates a risk of business impairment, thereby determining the fundamental value of this high-tech asset.
Competitor analysis
ARGX - Net Assets per Single Share|BNTX: Net Assets per Single Share|ABVX (Abivax Corp) - Accounting Value per Share|ADMA (admabiologics.com) - Net Assets per Single Share|Net Assets per Single Share Protagonist|Immunovant Inc - Share Book Value|Book Value per Share KNSA|GRFS (Grifols Biemat) - Accounting Value of a Share|Book Value per Share ADPT (Adaptive Biotechnologies)|Book Value per Share celldex.com CLDX|AUPH - Net Assets per Single Share|Accounting Value of a Share BCRX (BioCryst Pharmaceuticals, Inc.)|Vera Pharma (VERA) - Net Assets per Single Share|Accounting Value per Share Dianthus Corp|PHVS (Pharvaris N.V.) - Book Value per Share|Book Value per Share AbCellera Corp|Accounting Value per Share TRML (Tourmaline Bio)|PGEN (Precigen Inc) - Accounting Value of a Share|Book Value per Share PHAR (Pharming)|Net Assets per Share Nektar Corp (NKTR)|UPB - Net Assets per Single Share|zenasbio.com (ZBIO) - Accounting Value per Share|Immunome (IMNM) - Net Assets per Single Share|Accounting Value per Share Gossamer Bio Inc|Accounting Value per Share KALV|Book Value per Share Septerna Pharma|Net Assets per Single Share Pieris Pharmaceuticals (PVLA)|savarapharma.com - Equity per Share|Book Value per Share RIGL (Rigel Pharmaceuticals, Inc.)|AnaptysBio Inc (ANAB) - Net Asset Value per Share|Astria Pharma - Book Value per Share|Net Asset Value per Share enGene Corp|RAPT Therapeutics, Inc. (RAPT) - Net Assets per Single Share|Equity per Share JBIO|Net Assets per Single Share Aclaris Therapeutics, Inc.|Net Assets per Single Share KYTX|Book Value per Share TLSA|Net Assets per Share Cabaletta Bio Inc|Ventyx Biosciences - Accounting Value per Share|theratech.com - Net Assets per Single Share|Avalo Therapeutics - Book Value per Share|Net Asset Value per Share Eledon Pharmaceuticals Inc.|AGEN (Agenus Inc) - Accounting Value per Share|Equity per Share CLYM|Accounting Value per Share ZURA|ATYR: Accounting Value of a Share|Accounting Value per Share ADAG (Adagene)|Book Price of a Share IMA|Book Value per Share STTK (Shattuck Labs)|Accounting Value of a Share EQ|Connect Pharma - Book Value per Share|Net Asset Value per Share Immunic, Inc.|atarabio.com (ATRA) - Net Assets per Single Share|InflaRx - Accounting Value of a Share|XFOR (X4 Pharma) - Book Value per Share|Book Value per Share Adicet|Net Assets per Single Share Celularity Inc. (CELU)|INMB: Share Book Value|Book Value per Share BRNS (Barinthus Biotherapeutics plc)|Kezar Life Sciences Inc. (KZR) - Net Asset Value per Share|SABS: Accounting Value per Share|AKTX - Book Value per Share|QTTB (q32bio.com) - Accounting Value per Share|GOVX: Book Price of a Share|EDSA (Edesa Biotech) - Book Value per Share|iBio Inc (IBIO) - Net Assets per Share|Book Value per Share CARM|Accounting Value per Share XTL Bio XTLB|Net Assets per Single Share Bolt Biotherapeutics, Inc. BOLT|Net Assets per Share HCW Biologics, Inc. (HCWB)|Aptevo - Book Value per Share|Net Asset Value per Share AIM ImmunoTech, Inc.|aditxt.com (ADTX) - Net Assets per Single Share|Equity per Share GRI|Net Assets per Single Share XORTX Therapeutics Inc.|Net Assets per Single Share HIND|Accounting Value per Share REVB (Revelation Biosciences, Inc.)|Net Assets per Single Share INDP (Indaptus Therapeutics Inc)|Net Assets per Single Share Scinai SCNI|CALI (CalciMedica Inc) - Share Book Value|Affimed Therapeutics - Book Value per Share|Accounting Value of a Share ALLK (Allakos Inc.)|HOOK: Book Value per Share|IGM Biosciences (IGMS) - Book Value per Share|Net Assets per Single Share iTeos|OCEA: Accounting Value of a Share|Net Assets per Single Share TC Biopharm (TCBP)|Accounting Value per Share thirdharmonicbio.com THRD